Unseen Biometrics ApS

Fruebjergvej 3 2100 København Ø Denmark

CVR no. 40 04 65 85

Annual report 2021/22

The annual report was presented and approved at the Company's annual general meeting on

24 June 2022

<u>Jens Bøttcher Gandløse</u> Chairman of the annual general meeting

Contents

Statement by the Executive Board	2
Auditor's report on the compilation of financial statements	3
Management's review	4
Company details	4
Operating review	5
Financial statements 1 April – 31 March	6
Income statement	6
Balance sheet	7
Statement of changes in equity	9
Notes	10

Statement by the Executive Board

The Executive Board has today discussed and approved the annual report of Unseen Biometrics ApS for the financial year 1 April 2021 – 31 March 2022.

The annual report, which has not been audited, is presented in accordance with the Danish Financial Statements Act.

In our opinion, the financial statements give a true and fair view of the Company's assets, liabilities and financial position at 31 March 2022 and of the results of the Company's operations for the financial year 1 April 2021 - 31 March 2022.

Further, in our opinion, the Management's review gives a fair review of the matters discussed in the Management's review.

We recommend that the annual report be approved at the annual general meeting.

Copenhagen, 24 June 2022 Executive Board:

Johan Bruun Hartmann

Jens Bøttcher Gandløse

Moritz Emanuel Beber

Management confirms that the Company fulfils the requirements to be exempt of audit.



Auditor's report on the compilation of financial statements

To the Management of Unseen Biometrics ApS

We have compiled the financial statements of Unseen Biometrics ApS for the financial year 1 April 2021 – 31 March 2022 based on the Company's bookkeeping records and other information provided by you.

The financial statements comprise income statement, balance sheet, statement of changes in equity and notes, including accounting policies.

We performed our work in accordance with ISRS 4410 Compilation Engagements.

We have applied our professional expertise in accounting and financial reporting to assist you in the preparation and presentation of these financial statements in accordance with the Danish Financial Statements Act. We have complied relevant provisions of the Auditor Act, including the requirements for independence, and International Ethics Standards Board for Accountants' International Code of Ethics for Professional Accountants (IESBA Code), which is based on fundamental principles of integrity, objectivity, professional competence and due care.

These financial statements and the accuracy and completeness of the information used to compile them are your responsibility.

Since a compilation engagement is not an assurance engagement, we are not required to verify the accuracy or completeness of the information you provided to us to compile these financial statements. Accordingly, we do not express an audit opinion or a review conclusion as to whether these financial statements are prepared in accordance with the Danish Financial Statements Act.

Copenhagen, 24 June 2022 **KPMG** Statsautoriseret Revisionspartnerselskab CVR no. 25 57 81 98

Morten Høgh-Petersen State Authorised Public Accountant mne34283

Management's review

Company details

Unseen Biometrics ApS Fruebjergvej 3 2100 København Ø Denmark

Telephone:

26131426

CVR no.: Established: Registered office: Financial year: 40 04 65 85 21 November 2018 Copenhagen 1 April – 31 March

Executive Board

Johan Bruun Hartmann Jens Bøttcher Gandløse Moritz Emanuel Beber

Management's review

Operating review

Principal activities

The Company's main activities are to operate as a commercial Biotech company within the field of Next Generation Microbiome Analysis.

Development in activities and financial position

The Company's income statement for 2021/2022 shows a loss of DKK -681,049 as against DKK 990,793 in 2020/2021. Equity in the Company's balance sheet at 31 March 2022 stood at DKK 1,186,101 as against DKK 1,867,150 at 31 March 2021.

Events after the balance sheet date

Subsequent to the balance sheet date no events have occured after the financial year-end, which could significantly affect the company's financial position.

Income statement

DKK	Note	2021/2022	2020/2021
Gross profit/loss		-318,168	1,179,581
Staff costs	2	-624,653	0
Profit/loss before financial expenses		-942,821	1,179,581
Other financial expenses		-4,318	-100
Profit/loss before tax		-947,139	1,179,481
Tax on profit/loss for the year	3	266,090	-188,688
Profit/loss for the year		-681,049	990,793
Proposed profit appropriation/distribution of loss			
Reserve for development cost		-274	836,694
Retained earnings		-680,775	154,099

-681,049

____ =

990,793

=

Balance sheet

ОКК	Note	31/3 2022	31/3 2021
ASSETS			
Fixed assets			
Intangible assets			
Development projects in progress		2,087,859	1,212,961
Investments			
Deposits		29,906	29,906
Total fixed assets		2,117,765	1,242,867
Current assets			
Receivables			
Trade receivables		143,155	191,875
Other receivables		0	375,000
Corporation tax		192,555	47,302
		335,710	614,177
Cash at bank and in hand		73,822	693,744
Total current assets		409,532	1,307,921
TOTAL ASSETS		2,527,297	2,550,788

Balance sheet

DKK	Note	31/3 2022	31/3 2021
EQUITY AND LIABILITIES			
Equity			
Contributed capital		147,180	147,180
Reserve for development costs		945,836	946,110
Retained earnings		93,085	773,860
Total equity		1,186,101	1,867,150
Provisions			
Provisions for deferred tax		192,502	266,037
Total provisions		192,502	266,037
Liabilities other than provisions			
Current liabilities other than provisions			
Trade payables		66,840	130,495
Payables to related parties		200,000	200,000
Other payables		881,854	87,106
		1,148,694	417,601
Total liabilities other than provisions		1,148,694	417,601
TOTAL EQUITY AND LIABILITIES		2,527,297	2,550,788
Contractual obligations, contingencies, etc.	4		

Statement of changes in equity

Contributed capital	Reserve for development costs	Retained earnings	Total
147,180	946,110	773,860	1,867,150
0	-274	-680,775	-681,049
147,180	945,836	93,085	1,186,101
	capital 147,180 0	Contributed capitaldevelopment costs147,180946,1100-274	Contributed capitaldevelopment costsRetained earnings147,180946,110773,8600-274-680,775

Financial statements 1 April – 31 March

Notes

1 Accounting policies

The annual report of Unseen Biometrics ApS for 2021/22 has been prepared in accordance with the provisions applying to reporting class B entities under the Danish Financial Statements Act with opt-in from higher reporting classes.

The accounting policies used in the preparation of the financial statements are consistent with those of last year.

Income statement

Gross profit/loss

Pursuant to section 32 of the Danish Financial Statements Act, the Company has decided only to disclose gross profit.

Revenue

Revenue from the sale of services, is recognised on a straight-line basis in the income statement as the services are provided.

Services based on time spent are recognised in revenue as the work is performed.

Grants are recognised when it is fairly certain that the grant conditions will be complied with, and the grant will be received.

Cost of sales

Cost of sales comprises costs incurred to generate revenue for the year.

Other external costs

Other external costs comprise costs of distribution, administrative expenses, costs of premises, etc.

Staff costs

Staff costs comprise wages and salaries, including holiday allowance, pension and other social security costs. Refunds from public authorities are deducted from staff costs.

Financial expenses

Financial expenses comprise interest expense.

Tax on profit/loss for the year

Tax for the year comprises current corporation tax for the year and changes in deferred tax, including changes in tax rates. The tax expense relating to the profit/loss for the year is recognised in the income statement, and the tax expense relating to amounts directly recognised in equity is recognised directly in equity.

Notes

1 Accounting policies (continued)

Balance sheet

Intangible assets

Development projects

Development costs comprise costs, wages, salaries and amortisation directly and indirectly attributable to development activities.

Investments

Deposits are recognised at amortised cost.

Receivables

Receivables are measured at amortised cost.

Write-down is made for bad debt losses where there is an objective indication that a receivable has been impaired. If there is an objective indication that an individual receivable has been impaired, write-down is made on an individual basis.

Write-downs are calculated as the difference between the carrying amount of receivables and the present value of forecast cash flows, including the realisable value of any collateral received. The effective interest rate for the individual receivable or portfolio is used as discount rate.

Cash at bank and in hand

Cash at bank and in hand comprise cash and bank deposits.

Equity

Reserve for development costs

The reserve for development costs comprises capitalised development costs. The reserve cannot be used for dividends, distribution or to cover losses. If the recognised development costs are sold or in other ways excluded from the Company's operations, the reserve will be dissolved and transferred directly to the distributable reserves under equity. If the recognised development costs are written down, the part of the reserve corresponding to the write-down of the developments costs will be reversed. If a write-down of development costs is subsequently reversed, the reserve will be re-established. The reserve is reduced by amortisation of capitalised development costs on an ongoing basis.

Financial statements 1 April – 31 March

Notes

1 Accounting policies (continued)

Corporation tax and deferred tax

Current tax payable and receivable is recognised in the balance sheet as tax computed on the taxable income for the year, adjusted for tax on the taxable income of prior years and for tax paid on account.

Deferred tax is measured using the balance sheet liability method on all temporary differences between the carrying amount and the tax value of assets and liabilities based on the planned use of the asset or settlement of the liability. However, deferred tax is not recognised on temporary differences relating to goodwill non-deductible for tax purposes and on office premises and other items where the temporary differences arise at the date of acquisition without affecting either profit/loss or taxable income.

Deferred tax assets, including the tax value of tax loss carryforwards, are recognised at the expected value of their utilisation within the foreseeable future; either as a set-off against tax on future income or as a set-off against deferred tax liabilities in the same legal tax entity. Any deferred net assets are measured at net realisable value.

Deferred tax is measured in accordance with the tax rules and at the tax rates applicable at the balance sheet date when the deferred tax is expected to crystallise as current tax. Changes in deferred tax as a result of changes in tax rates are recognised in the income statement or equity, respectively.

Liabilities other than provisions

Other liabilities are measured at amortised cost.

Notes

	DKK	2021/2022	2020/2021
2	Staff costs		
	Wages and salaries	1,424,854	545,799
	Other social security costs	16,851	3,692
	CapItalised as development cost	-817,052	-549,491
		624,653	0
	Average number of full-time employees	6	4
3	Tax on profit/loss for the year		
	Tax credit scheme (development costs) for the year	-192,555	-47,302
	Deferred tax for the year	-73,535	235,990
		-266,090	188,688

4 Contractual obligations, contingencies, etc.

Operating lease obligations

The Company has entered into leases with a remaining term of 3 months and an average monthly lease payments of DKK 10 thousand, totalling DKK 30 thousand.